<div id="readability-page-1"><div>Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.U.S. markets rebounded this week as President Donald Trump softened his stance on trade and monetary policy. He indicated that tariffs on Chinese imports could decrease from the current 145% and affirmed his support for Federal Reserve Chair Jerome Powell, alleviating investor concerns about central bank independence.The S&amp;P 500 regained nearly 80% of its post-April 2 losses, with notable gains in technology stocks. ServiceNow NOW led with a 20% weekly increase, while Tesla TSLA surged 9.9% after CEO Elon Musk announced a reduced focus on the Department of Government Efficiency (DOGE).Despite the rally, economic indicators signaled caution. U.S. private sector growth slowed to a 16-month low, and consumer sentiment declined sharply. Inflation expectations rose, with one-year forecasts reaching 6.5%, the highest since 1981, suggesting persistent economic uncertainty.Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.The Bulls&#34;Netflix stock nears all-time high: What's going on?&#34;, by Adam Eckert, reports that Netflix Inc. NFLX shares approached record highs following strong Q1 earnings—$10.54 billion in revenue and $6.61 EPS—driven by robust subscription and advertising growth, with analysts raising price targets up to $1,514 and highlighting the company's insulation from global tariffs due to its digital-only business model.&#34;Why Is Summit Therapeutics Stock Soaring On Wednesday?&#34;, by Vandana Singh, reports that Summit Therapeutics Inc. SMMT shares surged after partner Akeso, Inc. announced that their Phase 3 HARMONi-6 trial met its primary endpoint, with ivonescimab plus chemotherapy showing a statistically significant improvement in progression-free survival over BeiGene Ltd.'s ONC tislelizumab combo in patients with advanced squamous non-small cell lung cancer.&#34;Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps&#34;, by Vandana Singh, reports that Novavax Inc. NVAX shares rose after the company stated its Biologics License Application is approvable and awaits FDA response following a post-marketing data request.For additional bullish calls of the past week, check out the following:Celestica Beats Q1 Estimates, Raises FY Outlook On ‘Strengthening Demand,' Shares SlideNvidia-Backed AI Startup Boasts ‘Extremely Rapid Revenue Growth' – JPMorgan Initiates With OverweightWhy Is Rocket Lab Stock Trading Higher On Thursday?The Bears&#34;Intel Q1 earnings: Revenue beat, EPS beat, shares tumble on weak guidance, chipmaker plans ‘swift actions' to drive efficiency&#34;, by Adam Eckert, reports that Intel Corp. INTC shares fell after the company reported first-quarter revenue of $12.67 billion and adjusted earnings of 13 cents per share, both surpassing analyst expectations, but issued a disappointing second-quarter revenue forecast of $11.2–$12.4 billion, prompting CEO Lip-Bu Tan to announce organizational streamlining and cost-cutting measures to enhance efficiency.&#34;Amazon stock downgraded, price target slashed as tariffs create uncertainty&#34;, by Erica Kollmann, reports that Amazon.com Inc. AMZN shares fell after Raymond James analyst Josh Beck downgraded the stock from Strong Buy to Outperform and cut the price target from $275 to $195, citing underestimated EBIT pressures from tariffs and macroeconomic headwinds.&#34;IBM Shares Slide Despite Better-Than-Expected Q1: Details&#34;, by Erica Kollmann, reports that International Business Machines Corp. IBM shares fell despite beating Q1 expectations with $1.60 EPS and $14.54 billion in revenue, as investors reacted to CEO Arvind Krishna's warning that economic uncertainty may cause clients to pause spending.For more bearish takes, be sure to see these posts:Enphase Energy Stock Is Tumbling Wednesday: Why Investors Are Selling SharesMeta's Fundamentals Look Fragile Heading Into Q1 Report, Analyst WarnsT-Mobile Shares Drop Despite Better-Than-Expected Q1 Report: DetailsKeep up with all the latest breaking news and trading ideas by following Benzinga on X.Image created using artificial intelligence via Midjourney.</div>This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</div>

SMMT

Benzinga reports on the recent rebound in U.S. markets, driven by President Trump's softened trade stance and support for the Federal Reserve. The S&P 500 regained nearly 80% of its losses, with tech stocks like ServiceNow and Tesla leading gains. However, economic indicators show caution, with private sector growth slowing and inflation expectations rising. Notable bullish stocks include Netflix, Novavax, and Summit Therapeutics, while bearish trends were seen in Intel, Amazon, and IBM due to weak guidance and economic uncertainty.

- U.S. markets rebounded as President Trump indicated potential tariff reductions on Chinese imports and expressed support for the Federal Reserve, leading to significant gains in technology stocks.  
- Despite this rally, economic indicators showed caution, with private sector growth slowing to a 16-month low and inflation expectations rising to 6.5%, the highest since 1981.  
- Notable stock movements included Netflix nearing record highs after strong earnings, while Intel and Amazon faced declines due to disappointing forecasts and tariff-related concerns.

Benzinga

Benzinga Bulls And Bears: Netflix, Novavax, Intel — And The Market Begins To Bounce Back